In a proof-of-concept RCT of 70 patients with severe femoropopliteal disease, sirolimus- vs paclitaxel-coated balloons gave greater 12-month improvement in endothelial function (40% vs 22%, P=0.023), with no difference in primary patency or target lesion revascularisation.
RCTn = 70
Rammos et al. Sirolimus Versus Paclitaxel Drug-Coated Ballons for Femoropopliteal Disease: The LIMUS FLOW Trial